In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

View From the Cath Lab: Hot Issues in Cardiology

Executive Summary

Three leading interventional cardiologists provide international perspectives on the most important issues confronting their specialty and how they will impact the device industry.

You may also be interested in...



TCT Highlights: Late Stent Thrombosis Controversy Continues

Late stent thrombosis (LST) concerns associated with drug-eluting stents (DES) dominated sessions at the 2006 Transcatheter Cardiovascular Therapeutics (TCT) annual conference, with additional long-term data presented on this topic. The general feeling expressed was one of relief that the expanded dataset presented at TCT showed the LST problem was not as bad as some had feared when the issue was discussed at the World Congress of Cardiology (WCC).

Will Late Loss Debate Stifle Device Start-Up Innovation?

The failure of Medtronic's Endeavor stent to hit its primary clinical trial goals has again spurred debate over surrogate endpoints, a poetntially big issue for small companies.

Will Late Loss Debate Stifle Device Start-Up Innovation?

The failure of Medtronic's Endeavor stent to hit its primary clinical trial endpoint has again spurred debate over surrogate endpoints, a potentially big issue for small companies.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel